LUCAR-G79 / Legend Biotech - LARVOL DELTA

A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Nanjing Legend Biotech Co. | N=42 ➔ 3 | Trial completion date: Apr 2030 ➔ Mar 2026 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2028 ➔ Mar 2026; pipeline adjustment

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Immunology

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Nanjing Legend Biotech Co. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Myositis • Systemic Lupus Erythematosus

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Nanjing Legend Biotech Co.

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Myositis • Systemic Lupus Erythematosus